CD19 CAR治疗急性淋巴细胞白血病的长期随访

N Engl J Med · 2018年2月1日 · Park 等 15 位作者

问这篇

一分钟了解要点53例复发B细胞急性淋巴细胞白血病成人接受19-28z CAR-T，中位总生存12.9个月。结果83%达到完全缓解，但中位无事件生存仅6.1个月，中位总生存12.9个月；14人（26%）出现重度细胞因子释放综合征，1人死亡。

不需要生物学背景，多打比方

正在获取全文并生成讲解（拿不到全文就依据摘要）…

已等待 0 秒大约需要 10–20 秒

可以先看别的，做好了会自动出现在这里。

这篇还没有动画

动画会把研究的流程、作用机制和关键结果一步一步演示出来，每一步都标明出自原文哪里。制作大约需要一两分钟。

目前只拿到了摘要全文暂时拿不到（可能不是免费全文）。下面是论文摘要。

摘要Abstract

摘要第 1 段问这一段

BACKGROUND: CD19-specific chimeric antigen receptor (CAR) T cells induce high rates of initial response among patients with relapsed B-cell acute lymphoblastic leukemia (ALL) and long-term remissions in a subgroup of patients.

摘要第 2 段问这一段

METHODS: We conducted a phase 1 trial involving adults with relapsed B-cell ALL who received an infusion of autologous T cells expressing the 19-28z CAR at the Memorial Sloan Kettering Cancer Center (MSKCC). Safety and long-term outcomes were assessed, as were their associations with demographic, clinical, and disease characteristics.

摘要第 3 段问这一段

RESULTS: A total of 53 adults received 19-28z CAR T cells that were manufactured at MSKCC. After infusion, severe cytokine release syndrome occurred in 14 of 53 patients (26%; 95% confidence interval [CI], 15 to 40); 1 patient died. Complete remission was observed in 83% of the patients. At a median follow-up of 29 months (range, 1 to 65), the median event-free survival was 6.1 months (95% CI, 5.0 to 11.5), and the median overall survival was 12.9 months (95% CI, 8.7 to 23.4). Patients with a low disease burden (<5% bone marrow blasts) before treatment had markedly enhanced remission duration and survival, with a median event-free survival of 10.6 months (95% CI, 5.9 to not reached) and a median overall survival of 20.1 months (95% CI, 8.7 to not reached). Patients with a higher burden of disease (≥5% bone marrow blasts or extramedullary disease) had a greater incidence of the cytokine release syndrome and neurotoxic events and shorter long-term survival than did patients with a low disease burden.

摘要第 4 段问这一段

CONCLUSIONS: In the entire cohort, the median overall survival was 12.9 months. Among patients with a low disease burden, the median overall survival was 20.1 months and was accompanied by a markedly lower incidence of the cytokine release syndrome and neurotoxic events after 19-28z CAR T-cell infusion than was observed among patients with a higher disease burden. (Funded by the Commonwealth Foundation for Cancer Research and others; ClinicalTrials.gov number, NCT01044069 .).

这篇对您：

讲解或动画有问题：